DEXCOM, INC. (DXCM): what the price requires
At today's price, DEXCOM, INC. (DXCM) is priced for today's economics sustained for ~8.2 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/DXCM
Headline
| Field | Value |
|---|---|
| Ticker | DXCM |
| Company | DEXCOM, INC. |
| Current price | $75.85/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 9.1% |
| Operating margin today | 18.4% |
| Margin compression implied | -9.3pp |
| Must persist for | 8.2y |
| Multiple paid | 35x operating income |
The operating-margin requirement is derived from the framework's value band at year 6, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 9.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.9 years.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | -0.42σ |
| sustained it ~8.2 years at this level | 25% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.97x | 5 | expensive |
| Earnings | 2.22x | 5 | expensive |
| Relative | 1.29x | 5 | expensive |
| Growth | 0.83x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $109.52 | 0.69x | yes | FCF base $1.7B, growth 16% (input: historical growth), terminal g 4.0%, WACC 8.9%, 6yr projection |
| DCF Exit Multiple | Growth | $91.65 | 0.83x | yes | Exit EV/EBITDA: 21.3x / 23.3x / 25.3x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $59.00 | 1.29x | yes | P/E 24x (static sector reference · 2026-04), scenarios: 19.6x / 24.0x / 28.4x (bear / base = reference held flat / bull), EV/EBITDA 16x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $25.55 | 2.97x | yes | BV/sh $7.51, ROE (TTM) 31.5%, ke 9.3% |
| Two-Stage Excess Return | Asset | $49.10 | 1.54x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $68.31 | 1.11x | yes | Rev $4.8B, growth 16% (input: historical growth; tapered), Terminal P/S: 5.1x / 6.2x / 7.3x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $81.55 | 0.93x | yes | EPS $2.33, growth 35% (input: historical EPS growth), PEG=0.92 (Undervalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $10.77 | 7.04x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.60B × (1−26%) / WACC 8.9% → EPV (no growth) |
| Residual Income | Asset | $39.25 | 1.93x | yes | BV $7.51 + 5yr PV of (ROE (TTM) 31.5% − Kₑ 9.3%) × BV; BV grows 8.8%/yr |
| Graham Number | Asset | $19.85 | 3.82x | yes | √(22.5 × EPS $2.33 × BVPS $7.51) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $51.99 | 1.46x | yes | EBITDA $1.29B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $38.72 | 1.96x | yes | FCF $1429.4M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $34.09 | 2.22x | yes | SBC-adj FCF $1.26B (FCF $1.43B − SBC $0.17B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $75.18 | 1.01x | yes | EPS $2.33 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $5.05 | 15.02x | yes | BV $7.51 × (ROIC 6.0% / WACC 8.9%) |
| P/Sales Sector | Relative | $48.96 | 1.55x | yes | Revenue $4.82B × sector P/S 4.0x |
| PEG Fair Value | Relative | $87.38 | 0.87x | yes | EPS $2.33 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $25.19 | 3.01x | yes | EPS $2.33 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $1.4b |
| Net debt / NOPAT (after-tax) | -2.20x (net cash) |
| Net debt / operating income (pre-tax) | -1.63x (net cash) |
| Interest coverage | 63.5x |
| Share count CAGR (buyback) | -2.1% |
| Burning cash | no |
Bullet Takeaways
DexCom is a recurring-revenue CGM device franchise: Q1 2026 revenue grew 15% to $1.19 billion (12% organic), full-year guidance is $5.16 to $5.25 billion (11 to 13% growth), and management raised its non-GAAP operating margin outlook to 23 to 23.5%.
The central risk is moat erosion: DexCom competes directly with Abbott and Medtronic/MiniMed, the competition has extended to the over-the-counter segment (Abbott's Libre Rio versus DexCom's Stelo), and gross-margin guidance of 63 to 64% was not raised despite the strong quarter.
Bull Case
Valuing DexCom is a medical-device problem, not a generic software-multiple problem, and that lens is the bull case. Continuous glucose monitors are recurring-revenue razor-and-blade devices: a patient adopts a sensor and reorders it indefinitely, so each new user is an annuity, not a one-time sale. That makes the relevant questions the size of the addressable patient pool, the reorder rate, and the gross margin on the consumable, and on all three DexCom screens well. Q1 2026 revenue grew 15% to $1.19 billion (12% organic), U.S. revenue rose 11% on expanded coverage and strong G7 15-day adoption, and international grew 26% as reported. Management guides full-year revenue to $5.16 to $5.25 billion, up 11% to 13%, and raised the non-GAAP operating margin outlook to 23% to 23.5%.
The second leg is the product cadence, which is what keeps a device company ahead of obsolescence. DexCom launched the G7 15-day system, the longest-wearing sensor in its class, and plans to convert nearly half its U.S. user base to it, a move that improves both patient experience and unit economics. It also extended its over-the-counter Stelo platform with Smart Meal Logging and is readying Smart Basal, pushing CGM beyond the insulin-using diabetic into the far larger population of type 2, prediabetic, and health-conscious consumers. Stelo's reported MARD accuracy of 8.3% is better than the competing over-the-counter sensor's 9.3%, the kind of clinical edge that matters in this category.
The third leg is the structural tailwind. The CGM market is large and growing, driven by the secular rise in diabetes, expanding reimbursement, and the over-the-counter expansion into wellness. DexCom is one of two scaled leaders in a category with high clinical switching costs once a patient and physician settle on a system. A 16%-plus historical growth company with annuity revenue, expanding margins, and a multi-product roadmap is exactly the kind of durable medtech compounder the forward-looking valuation methods support, with the DCF frames landing well above the current price.
Bear Case
The bear case on DexCom is moat erosion, and it is happening at both ends of the market at once. DexCom itself names the threat in its filing: it competes directly with the Diabetes Care division of Abbott Laboratories and with Medtronic's diabetes business (now spun out as MiniMed) [DXCM FY2025 10-K, accession 0001093557-26-000027], and it warns that its products may be rendered obsolete by technological breakthroughs in diabetes monitoring [DXCM FY2025 10-K, accession 0001093557-26-000027]. This is not a one-supplier category. Abbott's FreeStyle Libre franchise is a formidable, lower-priced competitor with enormous scale, and the competitive front has now extended to the over-the-counter consumer segment, where Abbott received FDA clearance for the Libre Rio aimed at type 2 diabetics not on insulin. A duopoly racing each other on price and features is a different investment than a sole-source monopoly, and the pricing pressure shows up in gross margins.
The margin signal is worth dwelling on. Despite a strong Q1, management did not raise gross-margin guidance, citing geopolitical uncertainty affecting freight and shipping, and the 63% to 64% gross-margin range is below where a true monopoly medtech would sit. Hardware-led CGM is capital-intensive and competitive enough that margins are bounded, and the over-the-counter push, while expanding the market, brings lower price points and direct-to-consumer acquisition costs that can dilute profitability even as it adds volume.
The valuation leaves no room for the moat to slip. At $72.48 the stock trades at roughly 33 times operating income, and the inversion runs in duration mode, requiring the elevated economics to persist for about eight years, with both the cohort and fade signals tripped and the rate-robustness check failing. The composite reads high. The static methods sit far below the price (earnings-power and asset frames at a fraction of $72), and only the growth-DCF methods reach it, by extrapolating 16% growth. If Abbott continues to take share, if the OTC expansion compresses blended margins, or if a next-generation technology (a longer-wear or implantable sensor from a rival) leapfrogs the G7, the durability the price assumes erodes, and a stock priced for eight years of uninterrupted compounding has a long way to fall toward the static methods.
Valuation
DexCom is best valued as a recurring-revenue medical-device franchise, and on that basis the price is a quality-and-durability premium that the forward methods support and the static ones do not. At $72.48 the inversion reads roughly a 33 times operating-income multiple and runs in duration mode, meaning the price is justified by assuming the elevated economics persist for about eight years rather than by an extreme growth rate. The composite is high, both the cohort and fade signals are tripped, and the rate-robustness check fails, all flags that the priced-in durability is long and rate-sensitive.
The method families split. The growth-DCF methods reach above the price (DCF Perpetual Growth about $122, DCF Exit Multiple about $97.93), extrapolating roughly 16% growth from the consumable annuity. The relative-multiple method is near the price. The static asset and earnings-power frames sit well below, because a device company carries real capital intensity and its trailing earnings understate the annuity value the market is paying for.
The practical read: this is a high-quality medtech compounder priced for a long runway in a competitive duopoly. The annuity economics are genuine (15% revenue growth, 23%-plus operating margin guidance, a strong product roadmap), and a leading CGM franchise can deserve a premium. But the buyer at $72 is underwriting about eight years of sustained compounding against Abbott and the OTC margin question, with the static methods anchored in the $35 to $55 range. The valuation rewards durable share and margin and punishes any moat erosion.
Catalysts
The most recent catalyst was a Q1 2026 report at the end of April. Revenue grew 15% to $1.19 billion (12% organic), net income was $199.5 million, U.S. revenue rose 11% on expanded coverage and G7 15-day adoption, and international grew 26% as reported. DexCom reaffirmed full-year revenue guidance of $5.16 to $5.25 billion (11 to 13% growth) and raised its non-GAAP operating margin outlook to 23 to 23.5%, while holding gross-margin guidance at 63 to 64% citing geopolitical and shipping uncertainty. The stock dipped after hours despite the beats, reflecting how much growth is already priced in.
Product launches are the forward catalysts. The G7 15-day system is rolling out with a plan to convert nearly half the U.S. user base, and the over-the-counter Stelo platform gained Smart Meal Logging with Smart Basal in the pipeline, extending CGM into the larger non-insulin and wellness markets. The pace of G7 15-day conversion and Stelo's traction in the consumer channel are the metrics that determine whether the growth runway extends.
Competition is the catalyst to watch most closely. Abbott received FDA clearance for the over-the-counter Libre Rio for type 2 diabetics not on insulin, opening a direct head-to-head in the consumer category roughly three months after DexCom's Stelo, where DexCom's reported 8.3% MARD accuracy edges Abbott's 9.3%. Share trends between the two leaders, any new-technology entrant, reimbursement decisions, and blended-margin trajectory as the OTC mix grows are the items that govern whether the durability the price assumes holds. The next quarterly print and competitive launches are the near-term markers.
Sources: https://finance.yahoo.com/sectors/healthcare/articles/dexcom-inc-dxcm-q1-2026-071832863.html , https://www.drugdeliverybusiness.com/dexcom-q1-2026-stock-sales-growth/ , https://www.medtechdive.com/news/dexcom-stelo-over-the-counter-cgm/709416/ , https://www.medicaldevice-network.com/features/inside-dexcom-strategy-to-stay-ahead-in-the-13-bn-cgm-market/
Peer Cohorts (Per Segment, With Filing Citations)
DexCom (single reportable segment - CGM disposable sensors and Reusable Hardware) (reported)
- PODD (INSULET CORPORATION)
- (no filing in the citation store)
- TNDM (Tandem Diabetes Care, Inc.)
- (no filing in the citation store)
- IRTC (iRhythm Holdings, Inc.)
- (no filing in the citation store)
- MMSI (MERIT MEDICAL SYSTEMS INC)
- (no filing in the citation store)
- BSX (BOSTON SCIENTIFIC CORP)
- (no filing in the citation store)
- PEN (Penumbra, Inc)
- (no filing in the citation store)
- GMED (GLOBUS MEDICAL, INC.)
- (no filing in the citation store)
- EW (EDWARDS LIFESCIENCES CORPORATION)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.